Cargando…
Enhanced Potency of GalNAc-Conjugated Antisense Oligonucleotides in Hepatocellular Cancer Models
Antisense oligonucleotides (ASOs) are a novel therapeutic approach to target difficult-to-drug protein classes by targeting their corresponding mRNAs. Significantly enhanced ASO activity has been achieved by the targeted delivery of ASOs to selected tissues. One example is the targeted delivery of A...
Autores principales: | Kim, Youngsoo, Jo, Minji, Schmidt, Joanna, Luo, Xiaolin, Prakash, Thazha P., Zhou, Tianyuan, Klein, Stephanie, Xiao, Xiaokun, Post, Noah, Yin, Zhengfeng, MacLeod, A. Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6731179/ https://www.ncbi.nlm.nih.gov/pubmed/31303442 http://dx.doi.org/10.1016/j.ymthe.2019.06.009 |
Ejemplares similares
-
Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor
por: Schmidt, Karsten, et al.
Publicado: (2017) -
GalNAc Conjugation Attenuates the Cytotoxicity of Antisense Oligonucleotide Drugs in Renal Tubular Cells
por: Sewing, Sabine, et al.
Publicado: (2018) -
Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides
por: Yamamoto, Tsuyoshi, et al.
Publicado: (2021) -
Integrated Assessment of Phase 2 Data on GalNAc(3)-Conjugated 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides
por: Baker, Brenda F., et al.
Publicado: (2023) -
Disposition and Pharmacology of a GalNAc(3)-conjugated ASO Targeting Human Lipoprotein (a) in Mice
por: Yu, Rosie Z, et al.
Publicado: (2016)